EXCLSUIVE: Alzamend Neuro Tells Benzinga Co Submits IND Application To The US FDA For Phase IIA Clinical Trial Of AL001 In Bipolar Disorder Patients
Portfolio Pulse from Benzinga Newsdesk
Alzamend Neuro has submitted an Investigational New Drug (IND) application to the US FDA for a Phase IIA clinical trial of AL001 in bipolar disorder patients.
August 30, 2023 | 11:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alzamend Neuro's submission of an IND application to the FDA for a Phase IIA clinical trial of AL001 could potentially impact the company's stock.
The submission of an IND application to the FDA is a significant step in the drug development process. If approved, it could potentially lead to a new treatment option for bipolar disorder, which could positively impact Alzamend Neuro's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100